ArticleUrology research & practice2025
Interim Results of Rigicon Penile Prosthesis Implantation in a Single Center: The Largest Series in Türkiye.
Article in Urology research & practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- [Penile implant surgery in Germany-effective, established, yet underused].Urologie (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze data from patient information forms (PIFs) submitted to the manufacturer of a new 3-piece inflatable penile prosthesis (IPP), the Rigicon Infla10® , to summarize interim outcomes of 250 implantations in a single center, which is the largest series in Türkiye. Methods: A retrospective review of PIFs from 250 patients implanted with the IPP between January 2021 and December 2023 was performed to assess patient characteristics, surgical data, device durability, patient satisfaction, and rates of reoperation for any reason. Results: The mean ± SD (range) follow-up was 21.2 ± 8.7 (6-36) months and the mean ± SD patient age was 56.2 ± 9.1 years. The average surgical time was 47 minutes. Of the total, 2.4% of devices required removal or revision. Mechanical failure of the device was reported in 3 patients (1.2%). One patient (0.4%) required revision for noise during pumping. Two patients (0.8%) requested device removal because of dissatisfaction. No infections were observed in this series. A total of 97.6% of the Rigicon Infla10® devices were free from explant or revision. The satisfaction rate based on a single question asked to the patient by the surgeon 6 months after surgery was 98.4%. Conclusion: All Rigicon Infla10® IPPs implanted in the center prior to January 2024 were included in the retrospective analysis of volunteered PIFs. Initial durability from reoperation was demonstrated to be superior compared to other contemporary devices. Additionally, high satisfaction with treatment outcomes was reported by 92.4% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.